Andrenocortical Carcinomas: Twelve-year Prospective Experience
Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ±...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tauchmanovà, Libuse [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2004 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Société Internationale de Chirurgie 2004 |
|---|
| Übergeordnetes Werk: |
Enthalten in: World Journal of Surgery - Springer-Verlag, 1996, 28(2004), 9 vom: 19. Aug., Seite 896-903 |
|---|---|
| Übergeordnetes Werk: |
volume:28 ; year:2004 ; number:9 ; day:19 ; month:08 ; pages:896-903 |
| Links: |
|---|
| DOI / URN: |
10.1007/s00268-004-7296-5 |
|---|
| Katalog-ID: |
SPR003401936 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR003401936 | ||
| 003 | DE-627 | ||
| 005 | 20230520010246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201001s2004 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00268-004-7296-5 |2 doi | |
| 035 | |a (DE-627)SPR003401936 | ||
| 035 | |a (SPR)s00268-004-7296-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tauchmanovà, Libuse |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Andrenocortical Carcinomas: Twelve-year Prospective Experience |
| 264 | 1 | |c 2004 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Société Internationale de Chirurgie 2004 | ||
| 520 | |a Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences. | ||
| 650 | 4 | |a Adrenal Mass |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Adrenocortical Carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mitotane |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Androgen Excess |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a High Mitotic Rate |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Colao, Annamaria |4 aut | |
| 700 | 1 | |a Marzano, Luigi Antonio |4 aut | |
| 700 | 1 | |a Sparano, Lucianna |4 aut | |
| 700 | 1 | |a Camera, Luigi |4 aut | |
| 700 | 1 | |a Rossi, Annalisa |4 aut | |
| 700 | 1 | |a Palmieri, Giovanna |4 aut | |
| 700 | 1 | |a Marzano, Ettore |4 aut | |
| 700 | 1 | |a Salvatore, Marco |4 aut | |
| 700 | 1 | |a Pettinato, Guido |4 aut | |
| 700 | 1 | |a Lombardi, Gaetano |4 aut | |
| 700 | 1 | |a Rossi, Riccardo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World Journal of Surgery |d Springer-Verlag, 1996 |g 28(2004), 9 vom: 19. Aug., Seite 896-903 |w (DE-627)SPR003391159 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2004 |g number:9 |g day:19 |g month:08 |g pages:896-903 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00268-004-7296-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2004 |e 9 |b 19 |c 08 |h 896-903 | ||
| author_variant |
l t lt a c ac l a m la lam l s ls l c lc a r ar g p gp e m em m s ms g p gp g l gl r r rr |
|---|---|
| matchkey_str |
tauchmanovlibusecolaoannamariamarzanolui:2004----:nrncriacrioatevyapopc |
| hierarchy_sort_str |
2004 |
| publishDate |
2004 |
| allfields |
10.1007/s00268-004-7296-5 doi (DE-627)SPR003401936 (SPR)s00268-004-7296-5-e DE-627 ger DE-627 rakwb eng Tauchmanovà, Libuse verfasserin aut Andrenocortical Carcinomas: Twelve-year Prospective Experience 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2004 Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences. Adrenal Mass (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Androgen Excess (dpeaa)DE-He213 High Mitotic Rate (dpeaa)DE-He213 Colao, Annamaria aut Marzano, Luigi Antonio aut Sparano, Lucianna aut Camera, Luigi aut Rossi, Annalisa aut Palmieri, Giovanna aut Marzano, Ettore aut Salvatore, Marco aut Pettinato, Guido aut Lombardi, Gaetano aut Rossi, Riccardo aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 28(2004), 9 vom: 19. Aug., Seite 896-903 (DE-627)SPR003391159 nnns volume:28 year:2004 number:9 day:19 month:08 pages:896-903 https://dx.doi.org/10.1007/s00268-004-7296-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 28 2004 9 19 08 896-903 |
| spelling |
10.1007/s00268-004-7296-5 doi (DE-627)SPR003401936 (SPR)s00268-004-7296-5-e DE-627 ger DE-627 rakwb eng Tauchmanovà, Libuse verfasserin aut Andrenocortical Carcinomas: Twelve-year Prospective Experience 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2004 Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences. Adrenal Mass (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Androgen Excess (dpeaa)DE-He213 High Mitotic Rate (dpeaa)DE-He213 Colao, Annamaria aut Marzano, Luigi Antonio aut Sparano, Lucianna aut Camera, Luigi aut Rossi, Annalisa aut Palmieri, Giovanna aut Marzano, Ettore aut Salvatore, Marco aut Pettinato, Guido aut Lombardi, Gaetano aut Rossi, Riccardo aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 28(2004), 9 vom: 19. Aug., Seite 896-903 (DE-627)SPR003391159 nnns volume:28 year:2004 number:9 day:19 month:08 pages:896-903 https://dx.doi.org/10.1007/s00268-004-7296-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 28 2004 9 19 08 896-903 |
| allfields_unstemmed |
10.1007/s00268-004-7296-5 doi (DE-627)SPR003401936 (SPR)s00268-004-7296-5-e DE-627 ger DE-627 rakwb eng Tauchmanovà, Libuse verfasserin aut Andrenocortical Carcinomas: Twelve-year Prospective Experience 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2004 Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences. Adrenal Mass (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Androgen Excess (dpeaa)DE-He213 High Mitotic Rate (dpeaa)DE-He213 Colao, Annamaria aut Marzano, Luigi Antonio aut Sparano, Lucianna aut Camera, Luigi aut Rossi, Annalisa aut Palmieri, Giovanna aut Marzano, Ettore aut Salvatore, Marco aut Pettinato, Guido aut Lombardi, Gaetano aut Rossi, Riccardo aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 28(2004), 9 vom: 19. Aug., Seite 896-903 (DE-627)SPR003391159 nnns volume:28 year:2004 number:9 day:19 month:08 pages:896-903 https://dx.doi.org/10.1007/s00268-004-7296-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 28 2004 9 19 08 896-903 |
| allfieldsGer |
10.1007/s00268-004-7296-5 doi (DE-627)SPR003401936 (SPR)s00268-004-7296-5-e DE-627 ger DE-627 rakwb eng Tauchmanovà, Libuse verfasserin aut Andrenocortical Carcinomas: Twelve-year Prospective Experience 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2004 Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences. Adrenal Mass (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Androgen Excess (dpeaa)DE-He213 High Mitotic Rate (dpeaa)DE-He213 Colao, Annamaria aut Marzano, Luigi Antonio aut Sparano, Lucianna aut Camera, Luigi aut Rossi, Annalisa aut Palmieri, Giovanna aut Marzano, Ettore aut Salvatore, Marco aut Pettinato, Guido aut Lombardi, Gaetano aut Rossi, Riccardo aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 28(2004), 9 vom: 19. Aug., Seite 896-903 (DE-627)SPR003391159 nnns volume:28 year:2004 number:9 day:19 month:08 pages:896-903 https://dx.doi.org/10.1007/s00268-004-7296-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 28 2004 9 19 08 896-903 |
| allfieldsSound |
10.1007/s00268-004-7296-5 doi (DE-627)SPR003401936 (SPR)s00268-004-7296-5-e DE-627 ger DE-627 rakwb eng Tauchmanovà, Libuse verfasserin aut Andrenocortical Carcinomas: Twelve-year Prospective Experience 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2004 Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences. Adrenal Mass (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Androgen Excess (dpeaa)DE-He213 High Mitotic Rate (dpeaa)DE-He213 Colao, Annamaria aut Marzano, Luigi Antonio aut Sparano, Lucianna aut Camera, Luigi aut Rossi, Annalisa aut Palmieri, Giovanna aut Marzano, Ettore aut Salvatore, Marco aut Pettinato, Guido aut Lombardi, Gaetano aut Rossi, Riccardo aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 28(2004), 9 vom: 19. Aug., Seite 896-903 (DE-627)SPR003391159 nnns volume:28 year:2004 number:9 day:19 month:08 pages:896-903 https://dx.doi.org/10.1007/s00268-004-7296-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 28 2004 9 19 08 896-903 |
| language |
English |
| source |
Enthalten in World Journal of Surgery 28(2004), 9 vom: 19. Aug., Seite 896-903 volume:28 year:2004 number:9 day:19 month:08 pages:896-903 |
| sourceStr |
Enthalten in World Journal of Surgery 28(2004), 9 vom: 19. Aug., Seite 896-903 volume:28 year:2004 number:9 day:19 month:08 pages:896-903 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Adrenal Mass Adrenocortical Carcinoma Mitotane Androgen Excess High Mitotic Rate |
| isfreeaccess_bool |
false |
| container_title |
World Journal of Surgery |
| authorswithroles_txt_mv |
Tauchmanovà, Libuse @@aut@@ Colao, Annamaria @@aut@@ Marzano, Luigi Antonio @@aut@@ Sparano, Lucianna @@aut@@ Camera, Luigi @@aut@@ Rossi, Annalisa @@aut@@ Palmieri, Giovanna @@aut@@ Marzano, Ettore @@aut@@ Salvatore, Marco @@aut@@ Pettinato, Guido @@aut@@ Lombardi, Gaetano @@aut@@ Rossi, Riccardo @@aut@@ |
| publishDateDaySort_date |
2004-08-19T00:00:00Z |
| hierarchy_top_id |
SPR003391159 |
| id |
SPR003401936 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR003401936</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230520010246.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201001s2004 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00268-004-7296-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR003401936</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00268-004-7296-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tauchmanovà, Libuse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Andrenocortical Carcinomas: Twelve-year Prospective Experience</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Société Internationale de Chirurgie 2004</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adrenal Mass</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adrenocortical Carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mitotane</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Androgen Excess</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">High Mitotic Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Colao, Annamaria</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marzano, Luigi Antonio</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sparano, Lucianna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Camera, Luigi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rossi, Annalisa</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palmieri, Giovanna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marzano, Ettore</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Salvatore, Marco</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pettinato, Guido</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lombardi, Gaetano</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rossi, Riccardo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">World Journal of Surgery</subfield><subfield code="d">Springer-Verlag, 1996</subfield><subfield code="g">28(2004), 9 vom: 19. Aug., Seite 896-903</subfield><subfield code="w">(DE-627)SPR003391159</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:28</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:9</subfield><subfield code="g">day:19</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:896-903</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00268-004-7296-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">28</subfield><subfield code="j">2004</subfield><subfield code="e">9</subfield><subfield code="b">19</subfield><subfield code="c">08</subfield><subfield code="h">896-903</subfield></datafield></record></collection>
|
| author |
Tauchmanovà, Libuse |
| spellingShingle |
Tauchmanovà, Libuse misc Adrenal Mass misc Adrenocortical Carcinoma misc Mitotane misc Androgen Excess misc High Mitotic Rate Andrenocortical Carcinomas: Twelve-year Prospective Experience |
| authorStr |
Tauchmanovà, Libuse |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR003391159 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Andrenocortical Carcinomas: Twelve-year Prospective Experience Adrenal Mass (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Androgen Excess (dpeaa)DE-He213 High Mitotic Rate (dpeaa)DE-He213 |
| topic |
misc Adrenal Mass misc Adrenocortical Carcinoma misc Mitotane misc Androgen Excess misc High Mitotic Rate |
| topic_unstemmed |
misc Adrenal Mass misc Adrenocortical Carcinoma misc Mitotane misc Androgen Excess misc High Mitotic Rate |
| topic_browse |
misc Adrenal Mass misc Adrenocortical Carcinoma misc Mitotane misc Androgen Excess misc High Mitotic Rate |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
World Journal of Surgery |
| hierarchy_parent_id |
SPR003391159 |
| hierarchy_top_title |
World Journal of Surgery |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR003391159 |
| title |
Andrenocortical Carcinomas: Twelve-year Prospective Experience |
| ctrlnum |
(DE-627)SPR003401936 (SPR)s00268-004-7296-5-e |
| title_full |
Andrenocortical Carcinomas: Twelve-year Prospective Experience |
| author_sort |
Tauchmanovà, Libuse |
| journal |
World Journal of Surgery |
| journalStr |
World Journal of Surgery |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2004 |
| contenttype_str_mv |
txt |
| container_start_page |
896 |
| author_browse |
Tauchmanovà, Libuse Colao, Annamaria Marzano, Luigi Antonio Sparano, Lucianna Camera, Luigi Rossi, Annalisa Palmieri, Giovanna Marzano, Ettore Salvatore, Marco Pettinato, Guido Lombardi, Gaetano Rossi, Riccardo |
| container_volume |
28 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tauchmanovà, Libuse |
| doi_str_mv |
10.1007/s00268-004-7296-5 |
| title_sort |
andrenocortical carcinomas: twelve-year prospective experience |
| title_auth |
Andrenocortical Carcinomas: Twelve-year Prospective Experience |
| abstract |
Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences. © Société Internationale de Chirurgie 2004 |
| abstractGer |
Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences. © Société Internationale de Chirurgie 2004 |
| abstract_unstemmed |
Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences. © Société Internationale de Chirurgie 2004 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
9 |
| title_short |
Andrenocortical Carcinomas: Twelve-year Prospective Experience |
| url |
https://dx.doi.org/10.1007/s00268-004-7296-5 |
| remote_bool |
true |
| author2 |
Colao, Annamaria Marzano, Luigi Antonio Sparano, Lucianna Camera, Luigi Rossi, Annalisa Palmieri, Giovanna Marzano, Ettore Salvatore, Marco Pettinato, Guido Lombardi, Gaetano Rossi, Riccardo |
| author2Str |
Colao, Annamaria Marzano, Luigi Antonio Sparano, Lucianna Camera, Luigi Rossi, Annalisa Palmieri, Giovanna Marzano, Ettore Salvatore, Marco Pettinato, Guido Lombardi, Gaetano Rossi, Riccardo |
| ppnlink |
SPR003391159 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s00268-004-7296-5 |
| up_date |
2024-07-03T19:19:42.927Z |
| _version_ |
1803586773114159104 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR003401936</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230520010246.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201001s2004 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00268-004-7296-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR003401936</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00268-004-7296-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tauchmanovà, Libuse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Andrenocortical Carcinomas: Twelve-year Prospective Experience</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Société Internationale de Chirurgie 2004</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adrenal Mass</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adrenocortical Carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mitotane</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Androgen Excess</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">High Mitotic Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Colao, Annamaria</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marzano, Luigi Antonio</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sparano, Lucianna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Camera, Luigi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rossi, Annalisa</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palmieri, Giovanna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marzano, Ettore</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Salvatore, Marco</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pettinato, Guido</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lombardi, Gaetano</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rossi, Riccardo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">World Journal of Surgery</subfield><subfield code="d">Springer-Verlag, 1996</subfield><subfield code="g">28(2004), 9 vom: 19. Aug., Seite 896-903</subfield><subfield code="w">(DE-627)SPR003391159</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:28</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:9</subfield><subfield code="g">day:19</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:896-903</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00268-004-7296-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">28</subfield><subfield code="j">2004</subfield><subfield code="e">9</subfield><subfield code="b">19</subfield><subfield code="c">08</subfield><subfield code="h">896-903</subfield></datafield></record></collection>
|
| score |
7.4021006 |